102 related articles for article (PubMed ID: 24090479)
21. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.
Fine BA; Valente PT; Feinstein GI; Dey T
Gynecol Oncol; 2000 Jan; 76(1):33-9. PubMed ID: 10620438
[TBL] [Abstract][Full Text] [Related]
22. Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis.
Yang Q; Ye ZY; Zhang JX; Tao HQ; Li SG; Zhao ZS
Anat Rec (Hoboken); 2010 Dec; 293(12):2012-9. PubMed ID: 21089052
[TBL] [Abstract][Full Text] [Related]
23. [Expression of vascular endothelial growth factors (VEGF)-A, -C and -D and their prognostic significance and relationship with angio- and lymphangiogenesis in gastric cancer].
Wang XL; Ai ZS; Fang JP; Tang RY; Chen XM
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):837-43. PubMed ID: 19173829
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
[TBL] [Abstract][Full Text] [Related]
25. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Koutras AK; Antonacopoulou AG; Eleftheraki AG; Dimitrakopoulos FI; Koumarianou A; Varthalitis I; Fostira F; Sgouros J; Briasoulis E; Bournakis E; Bafaloukos D; Bompolaki I; Galani E; Kalogeras KT; Pectasides D; Fountzilas G; Kalofonos HP
Pharmacogenomics J; 2012 Dec; 12(6):468-75. PubMed ID: 21844885
[TBL] [Abstract][Full Text] [Related]
27. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
Coltelli L; Allegrini G; Orlandi P; Giuntini N; Alì G; Fioravanti A; Bona E; Barletta MT; Fontanini G; Del Tacca M; Danesi R; Falcone A; Bocci G
Pharmacogenomics; 2009 Aug; 10(8):1225-9. PubMed ID: 19663667
[TBL] [Abstract][Full Text] [Related]
28. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
29. Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.
Giampieri R; Salvatore L; Del Prete M; Prochilo T; D'Anzeo M; Loretelli C; Loupakis F; Aprile G; Maccaroni E; Andrikou K; Bianconi M; Bittoni A; Faloppi L; Demurtas L; Montironi R; Scarpelli M; Falcone A; Zaniboni A; Scartozzi M; Cascinu S
Sci Rep; 2016 Apr; 6():25195. PubMed ID: 27117754
[TBL] [Abstract][Full Text] [Related]
30. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer.
Carrillo de Santa Pau E; Arias FC; Caso Peláez E; Muñoz Molina GM; Sánchez Hernández I; Muguruza Trueba I; Moreno Balsalobre R; Sacristán López S; Gómez Pinillos A; del Val Toledo Lobo M
Cancer; 2009 Apr; 115(8):1701-12. PubMed ID: 19197998
[TBL] [Abstract][Full Text] [Related]
32. Glucose-regulated protein 78 silencing down-regulates vascular endothelial growth factor/vascular endothelial growth factor receptor 2 pathway to suppress human colon cancer tumor growth.
Kuo LJ; Hung CS; Chen WY; Chang YJ; Wei PL
J Surg Res; 2013 Nov; 185(1):264-72. PubMed ID: 23759331
[TBL] [Abstract][Full Text] [Related]
33. Expression of VEGF with tumor incidence, metastasis and prognosis in human gastric carcinoma.
Liu D; Wang N; Sun Y; Guo T; Zhu X; Guo J
Cancer Biomark; 2018; 22(4):693-700. PubMed ID: 29914006
[TBL] [Abstract][Full Text] [Related]
34. Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.
Paré-Brunet L; Sebio A; Salazar J; Berenguer-Llergo A; Río E; Barnadas A; Baiget M; Páez D
Pharmacogenomics J; 2015 Oct; 15(5):397-404. PubMed ID: 25707392
[TBL] [Abstract][Full Text] [Related]
35. miR-125a regulates angiogenesis of gastric cancer by targeting vascular endothelial growth factor A.
Dai J; Wang J; Yang L; Xiao Y; Ruan Q
Int J Oncol; 2015 Nov; 47(5):1801-10. PubMed ID: 26398444
[TBL] [Abstract][Full Text] [Related]
36. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
39. The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma.
Huang C; Huang R; Chang W; Jiang T; Huang K; Cao J; Sun X; Qiu Z
Neoplasma; 2012; 59(1):52-61. PubMed ID: 22082308
[TBL] [Abstract][Full Text] [Related]
40. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
